GAITHERSBURG, Md., Oct. 01, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Jody Lichaa has been named Vice President, Quality Assurance. Ms. Lichaa joined Novavax as the Executive Director, Quality Assurance in October 2011. She is responsible for providing strategy, oversight, and direction of the Company’s quality assurance.
Prior to joining Novavax, she was Senior Director, Quality at PharmAthene from 2005 until 2011, where she managed that company’s global QA/QC activities. Her prior experience includes quality assurance positions of increasing responsibility in a number of companies including Baxter, Shire and BioReliance. Ms. Lichaa received her B.S. in Toxicology from Northeastern University.
“Jody has successfully developed and managed a talented quality assurance team that has been instrumental in the ongoing development of our vaccine candidates,” said Stanley C. Erck, President and CEO. “Jody’s talent and expertise will continue to be critical as we prepare for Phase 3 development of our RSV F Vaccines.”
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations email@example.com 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. firstname.lastname@example.org email@example.com 212-845-4271